Key result
Administration of metoclopramide and ondansetron in healthy donkeys provoked significant alterations in cardiac indices, including increased fractional shortening compared with placebo.
Why the study?
The study aimed to evaluate cardiac indices using M-mode echocardiography after the administration of metoclopramide and ondansetron in donkeys.
Do metoclopramide and ondansetron alter echocardiographic cardiac indices in healthy donkeys?
Do metoclopramide and ondansetron alter echocardiographic cardiac indices in healthy donkeys?
p-value: p=0.031
Metoclopramide and ondansetron administration in donkeys causes significant transient alterations in echocardiographic cardiac indices, suggesting caution in animals with cardiac disease.
May indicate transient cardiac effects of metoclopramide in healthy donkeys; leaves open relevance to diseased animals or other species.
The aim of the present study was to evaluate cardiac indices using M-mode echocardiography after the administration of metoclopramide and ondansetron in donkeys. For this purpose, 10 apparently healthy Egyptian Baladi donkeys (Equus asinus) were used in a crossover prospective study. Two trials were conducted with the administration of metoclopramide hydrochloride anhydrous at a dose of 0.25 mg Kg−1 and ondansetron hydrochloride sodium at a dose of 0.15 mg Kg−1. The control group (placebo) received a total volume of 50 mL of isotonic saline at 0.9%. An echocardiographic examination was performed using a Digital Color Doppler Ultrasound System equipped with a 2–3.9 MHz phased array sector scanner transducer. In general, the fractional shortening (FS%) was significantly affected by the time for metoclopramide (p = 0.031) and ondansetron (p = 0.047) compared with those of placebo, with treatment with metoclopramide provoking significantly higher percentages of FS% at T60 (p = 0.009) and T90 (p = 0.028) compared with those for ondansetron and placebo. The interaction of time x treatment also showed a statistically significant alteration of FS% (p < 0.05), while the values returned to the basal line at T240. Metoclopramide induced a significant decrease in E-point to septal separation (EPSS) at T90 (p = 0.005), and T240 (p = 0.007) compared with ondansetron and placebo. The time x treatment interaction also showed a significant (p < 0.05) variation in EPSS, with values returning to the basal line at T300. Mitral valve opening velocity (DE SLP) values were significantly affected by time (p = 0.004) in the metoclopramide group compared with those of ondansetron and placebo. Administration of metoclopramide and ondansetron provoked significant alterations of DE SLP at T60 (p = 0.039), T120 (p = 0.036), and T300 (p = 0.005) compared with placebo. In conclusion, caution should be exercised when administering both treatments, especially to animals with suspected cardiac problems.
No takes yet. Share an insight, caveat, or question.
Marzok et al. (2023) studied Healthy (evaluating adverse cardiac effects) (n=10). Metoclopramide and ondansetron vs. Placebo (isotonic saline 0.9%) was evaluated on Fractional shortening (FS%) (p=0.031). Administration of metoclopramide and ondansetron in healthy donkeys provoked significant alterations in cardiac indices, including increased fractional shortening compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: